Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis

Akio Kimura, Masao Takemura, Ginette Serrero, Nobuaki Yoshikura, Yuichi Hayashi, Kuniaki Saito, Takashi Inuzuka

Research output: Contribution to journalArticle

Abstract

Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS )], 21 with carcinomas (10 CNS + ; 11 CNS ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.

Original languageEnglish
Pages (from-to)455-462
Number of pages8
JournalJournal of Neuro-Oncology
Volume137
Issue number3
DOIs
Publication statusPublished - 01-05-2018

Fingerprint

Cerebrospinal Fluid
Lymphoma
Central Nervous System
Neoplasm Metastasis
Carcinoma
Area Under Curve
Neoplasms
Central Nervous System Diseases
Enzyme Assays
Nervous System Diseases
ROC Curve

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Kimura, Akio ; Takemura, Masao ; Serrero, Ginette ; Yoshikura, Nobuaki ; Hayashi, Yuichi ; Saito, Kuniaki ; Inuzuka, Takashi. / Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis. In: Journal of Neuro-Oncology. 2018 ; Vol. 137, No. 3. pp. 455-462.
@article{818c7ad07e3642d0b680c1ce047c2a29,
title = "Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis",
abstract = "Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.",
author = "Akio Kimura and Masao Takemura and Ginette Serrero and Nobuaki Yoshikura and Yuichi Hayashi and Kuniaki Saito and Takashi Inuzuka",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s11060-017-2742-z",
language = "English",
volume = "137",
pages = "455--462",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis. / Kimura, Akio; Takemura, Masao; Serrero, Ginette; Yoshikura, Nobuaki; Hayashi, Yuichi; Saito, Kuniaki; Inuzuka, Takashi.

In: Journal of Neuro-Oncology, Vol. 137, No. 3, 01.05.2018, p. 455-462.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis

AU - Kimura, Akio

AU - Takemura, Masao

AU - Serrero, Ginette

AU - Yoshikura, Nobuaki

AU - Hayashi, Yuichi

AU - Saito, Kuniaki

AU - Inuzuka, Takashi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.

AB - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85042767843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042767843&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2742-z

DO - 10.1007/s11060-017-2742-z

M3 - Article

VL - 137

SP - 455

EP - 462

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -